alopecia

Posts

CTP-543 Phase 3 Trials in Alopecia Areata

CTP-543 Phase 3 Trials in Alopecia Areata

Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

Concert Pharmaceuticals, Inc today announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Concert discussed key aspects of its planned Phase 3 trials in adult patients with the U.S. Food and Drug Administration (FDA) at a recently conducted End-of-Phase 2 meeting. The Phase 3 program is intended to support filing of a New Drug Application for CTP-543.

“The planned initiation of the Phase 3 program, combined with the positive results of the Phase 2 dose ranging trial, show the continued momentum for our development of CTP-543 for patients with alopecia areata,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “Our Phase 3 clinical program is designed to confirm the previous findings observed with CTP-543 and advance our goal to bring an important new treatment option to people living with this life-altering autoimmune disease. Our intent is to initiate the Phase 3 program in the fourth quarter of 2020, pending COVID-19.”

The planned Phase 3 program for CTP-543 will include two randomized, double-blind, placebo-controlled clinical trials in adults at sites in the U.S., Canada and Europe. The Phase 3 program will evaluate the Severity of Alopecia Tool (SALT) score after 24 weeks of dosing in patients with moderate-to-severe alopecia areata. Key aspects of the Phase 3 trials include:

  • Patients age 18-65 years with ≥ 50% hair loss;
  • Approximately 700 patients are expected to enroll in each of the two Phase 3 trials;
  • Dosing: 8 mg twice-daily or 12 mg twice-daily of CTP-543 or placebo for 24 weeks; and
  • Primary endpoint: Percent of patients achieving a SALT score ≤20 at Week 24.

The End-of-Phase 2 meeting with the FDA was requested as a result of positive data from the dose-ranging Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. Patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks using SALT.

The 8 mg twice-daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving ≥ 75% and ≥ 90% relative change in SALT from baseline at 24 weeks. At Week 24, patients treated with 8 mg twice-daily and 12 mg twice-daily compared to placebo also rated significantly greater improvement in their alopecia areata on the Patient Global Impression of Improvement Scale. Treatment with CTP-543 was generally well tolerated, with one serious adverse event reported in the 12 mg dose group where the patient was able to complete the trial after a brief dose interruption.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

Source

Previous Posts

 

CTP-543 Phase 3 Trials in Alopecia Areata

CTP-543 Phase 3 Trials in Alopecia Areata

Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

Concert Pharmaceuticals, Inc today announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Concert discussed key aspects of its planned Phase 3 trials in adult patients with the U.S. Food and Drug Administration (FDA) at a recently conducted End-of-Phase 2 meeting. The Phase 3 program is intended to support filing of a New Drug Application for CTP-543.

“The planned initiation of the Phase 3 program, combined with the positive results of the Phase 2 dose ranging trial, show the continued momentum for our development of CTP-543 for patients with alopecia areata,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “Our Phase 3 clinical program is designed to confirm the previous findings observed with CTP-543 and advance our goal to bring an important new treatment option to people living with this life-altering autoimmune disease. Our intent is to initiate the Phase 3 program in the fourth quarter of 2020, pending COVID-19.”

The planned Phase 3 program for CTP-543 will include two randomized, double-blind, placebo-controlled clinical trials in adults at sites in the U.S., Canada and Europe. The Phase 3 program will evaluate the Severity of Alopecia Tool (SALT) score after 24 weeks of dosing in patients with moderate-to-severe alopecia areata. Key aspects of the Phase 3 trials include:

  • Patients age 18-65 years with ≥ 50% hair loss;
  • Approximately 700 patients are expected to enroll in each of the two Phase 3 trials;
  • Dosing: 8 mg twice-daily or 12 mg twice-daily of CTP-543 or placebo for 24 weeks; and
  • Primary endpoint: Percent of patients achieving a SALT score ≤20 at Week 24.

The End-of-Phase 2 meeting with the FDA was requested as a result of positive data from the dose-ranging Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. Patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks using SALT.

The 8 mg twice-daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving ≥ 75% and ≥ 90% relative change in SALT from baseline at 24 weeks. At Week 24, patients treated with 8 mg twice-daily and 12 mg twice-daily compared to placebo also rated significantly greater improvement in their alopecia areata on the Patient Global Impression of Improvement Scale. Treatment with CTP-543 was generally well tolerated, with one serious adverse event reported in the 12 mg dose group where the patient was able to complete the trial after a brief dose interruption.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

Source

Previous Posts

 

Alopecia Treatment Market

Alopecia Market Business Opportunities 2026

Alopecia Market Business Opportunities 2026

A new research study has been presented by UpMarketResearch.com offering a comprehensive analysis on the Global Alopecia (Hair Loss Treatment) Market where user can benefit from the complete market research report with all the required useful information about this market.

The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

 

The Alopecia (Hair Loss Treatment) Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Alopecia (Hair Loss Treatment) Market Report with Latest Industry Trends @ https://www.upmarketresearch.com/home/requested_sample/105857

Major Players Covered in this Report are:

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter & Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Global Alopecia (Hair Loss Treatment) Market Segmentation

This market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level.

Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:

Shampoos and Conditioners
Medicine Product

By Applications:

Men
Women

Global Alopecia (Hair Loss Treatment) Market Regions and Countries Level Analysis

 

Regional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Alopecia (Hair Loss Treatment) on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Alopecia (Hair Loss Treatment) sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted.

This study provides Alopecia (Hair Loss Treatment) sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Alopecia Market Business Opportunities 2026

Source

Previous Posts

 

Alopecia Treatment Market

Global Alopecia Treatment Market 2020

Global Alopecia Treatment Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026

Scope of the Report:

The worldwide market for Alopecia Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2026, from xx million US$ in 2020, according to a new study.

This report focuses on the Alopecia Treatment in the global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

Teva Pharmaceutical Industries
Merck
Johnson_Johnson
Reddy’s Laboratories
Cipla
Cellmid
Himalaya Drug
Taisho Pharmaceutical Holdings

Market Segment by Regions, regional analysis covers

North America (the United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Topical Drugs
Oral Drugs
Injectable
Hair Transplant Services
Other

Market Segment by Applications can be divided into

Hospitals
Dermatology And Trichology Clinics
Home Care Settings
Other

There are 15 Chapters to deeply display the global Alopecia Treatment market.

Chapter 1, to describe Alopecia Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Alopecia Treatment, with sales, revenue, and price of Alopecia Treatment, in 2018 and 2019;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2018 and 2019;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Alopecia Treatment, for each region, from 2015 to 2020;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2015 to 2020;
Chapter 12, Alopecia Treatment market forecast, by regions, type and application, with sales and revenue, from 2020 to 2026;
Chapter 13, 14 and 15, to describe Alopecia Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Global Alopecia Treatment Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026

Source

Previous Posts

 

Barbie Dolls with Vitiligo and Alopecia

Barbie Dolls with Vitiligo and Alopecia

Dr. Charles E. Crutchfield III Gets Caught Playing with the Newly Released Barbie Dolls with Vitiligo and Alopecia

Charles E. Crutchfield III, M.D.’s assistant, Kelly, was stunned when she stepped into his office and found him holding two Barbie Dolls on his desk.

“Wow, Dr. Crutchfield! I didn’t know you were into Barbie Dolls,” she commented with a disbelieving smile.

An Eagan, Minnesota, dermatologist, Dr. Crutchfield, responded, “Well, I didn’t know I was into Barbie Dolls until the recent release of the ‘Fashionista’ line of Barbie Dolls that are diverse and inclusive. As you know, at Crutchfield Dermatology we specialize in the treatment of vitiligo and alopecia. I’m particularly impressed with these new dolls that feature vitiligo and alopecia. I plan on showing them to some of my patients with those conditions. ”

A staple of American culture since 1959, Barbie kicked off the new decade with a renewed push for more diverse and inclusive offerings. According to a recent report on CNN, Mattel unveiled its Fashionistas 2020 collection to show off “a multidimensional view of beauty and fashion.”

The new range of dolls includes one with vitiligo. Recently, vitiligo was brought to the public’s consciousness by supermodel, Winnie Harlow. Vitiligo is a condition that causes the loss of skin pigment in blotches. Many patients with vitiligo experience self-consciousness and concern about being in public. When an icon like Barbie shares the condition, it goes a long way toward soothing that insecurity.

Mattel notes in a recent press release that “offering a doll with vitiligo in our main doll line allows kids to play out even more stories they see in the world around them.” The company worked with a dermatologist to make sure vitiligo was represented adequately in the design of the new doll. In addition to vitiligo, the other Barbie in Dr. Crutchfield’s office is made with hair loss, reflecting the realities of skin conditions called alopecia.

Dr. Crutchfield explained to Kelly that this wasn’t the first time Barbie showed empathy for the millions of children with personal characteristics unique from the original Barbie. “In 2019, Barbie introduced dolls with disabilities,” he continued. “One has a prosthetic limb, and another uses a wheelchair.”

Her teasing concluded, Kelly told Dr. Crutchfield she was utterly impressed by the updated Barbie she knew as a girl. The 21st Century version is now more diverse and inclusive.

“They have really resonated with my patients when I show them the dolls,” Dr. Crutchfield responded.

And show them he does.

“One of my adult patients with vitiligo started crying when she saw the doll. She told me she was teased so much as a child that she didn’t want to leave home. If she had that Barbie, she would have shown the other kids she was just one individual in a diverse world, and maybe they would not have bullied her that way.”

Dr. Crutchfield is happy to show off his new love of Barbie Dolls, especially since he specializes in the treatment of vitiligo and alopecia.

“I’ll gladly take a little ribbing from friends and colleagues if it gets us closer to a world where no child is afraid to leave home because of a skin or other condition.”

Way to go, Barbie and Dr. Crutchfield!

About Charles E. Crutchfield III, M.D.:

Charles E. Crutchfield III, M.D. is a graduate of the Mayo Clinic Medical School and a Clinical Professor of Dermatology at the University of Minnesota Medical School. He currently is the Medical Director of Crutchfield Dermatology in Eagan, (serving the greater Minneapolis-St. Paul area), Minnesota. Dr. Crutchfield is an annual selection of the “Top Doctors” issue of Mpls. St. Paul magazine. He is the only dermatologist to have been selected as a “Best Doctor for Women” by Minnesota Monthly magazine since the inception of the survey.

Dr. Crutchfield has been selected as one of the “Best Doctors in America,” an honor awarded to only 4% of all practicing physicians. Dr. Crutchfield is the co-author of a children’s book on sun protection and dermatology textbook. He is a member of the AΩA National Medical Honor Society, an expert consultant for WebMD and CNN, and a recipient of the Karis Humanitarian Award from the Mayo Clinic School of Medicine.

Dr. Crutchfield was also given “first a physician” award, Healthcare Hero, 100 most influential healthcare leaders in Minnesota, and one of the Top 100 African –American Newsmakers in the United States by TheGrio, an affiliate of NBC News. https://en.wikipedia.org/wiki/Grio_Awards

Dr. Charles E. Crutchfield III Gets Caught Playing with the Newly Released Barbie Dolls with Vitiligo and Alopecia

Source

Previous Posts

 

Male Androgenetic Alopecia

Alopecia Augmented Expansion to be Registered by 2019-2025

Alopecia Augmented Expansion to be Registered by 2019-2025

Alopecia (Hair Loss Treatment) Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The recently published research report sheds light on critical aspects of the global Alopecia (Hair Loss Treatment) market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis.

The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Alopecia (Hair Loss Treatment) market.

The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors.

The report profiles leading companies of the global Alopecia (Hair Loss Treatment) market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

The recently published study includes information on key segmentation of the global Alopecia (Hair Loss Treatment) market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Alopecia (Hair Loss Treatment) market study allows their readers to understand the difference between players and how they are operating amounts themselves on a global scale.

The research study gives deep insight into the current and future trends of the market along with the opportunities for the new players who are in the process of entering global Alopecia (Hair Loss Treatment) market.

Market dynamic analysis such as market drivers, market restraints is explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations to improve their business on a global scale.

The readers of the Alopecia (Hair Loss Treatment) Market report can also extract several key insights such as the market size of varies products and application along with their market share and growth rate. The report also includes information for the next five years as forested data and past five years as historical data and the market share of the several key information.

Make An Enquiry About This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2578095&source=atm

Global Alopecia (Hair Loss Treatment) Market by Companies:

The company profile section of the report offers great insights such as market revenue and market share of global Alopecia (Hair Loss Treatment) market. Key companies listed in the report are:

The following manufacturers are covered:

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter & Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Segment by Regions

North America
Europe
China
Japan
Southeast Asia
India

Segment by Type

Shampoos and Conditioners
Medicine Product

Segment by Application

Men
Women

Global Alopecia (Hair Loss Treatment) Market by Geography:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)
Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
North America (the United States, Mexico, and Canada.)
South America (Brazil etc.)
The Middle East and Africa (GCC Countries and Egypt.)

Alopecia Augmented Expansion to be Registered by 2019-2025

Source

Previous Posts

 

Global Alopecia Treatment Market

Global Alopecia Treatment Market and Market Insights

Global Alopecia Treatment Market and Market Insights

Alopecia is the condition described for excessive hair damage or hair loss. Alopecia treatment plays a major role in advanced healthcare, as it aids in the prevention of hair fall and regrowth of hair. The unhealthy lifestyle, ageing, and hormonal imbalance are some of the factors leading to alopecia condition.

The global alopecia treatment market size was valued at US$ 7,325.0 million in 2017 and is expected to exhibit a CAGR of 4.9% over the forecast period (2018 and 2026).

Increasing product approvals, product launches, and robust pipelines are expected to propel the market growth

Rising product launch and robust pipelines are expected to drive the global alopecia treatment market. For instance, in November 2018, Fidia Pharma launched Trinov hair growth lotion for hair growth in Italy.

Furthermore, in September 2018, Eli Lilly and Company initiated phase 2 clinical trial to assess the safety and efficacy of Baricitinib drug in treating patients with alopecia areata.

The study is estimated to complete in August 2022.

Rising initiatives such as crowdfunding campaigns and increasing collaboration by the market players are expected to bolster the market growth. For instance, in 2018, HairClone, a U.K. based company working on cellular hair restoration therapies, launched its public crowdfunding campaign.

The company collaborated with Capital Cell, a crowdfunding company. Similarly, in May 2013, RepliCel Life Sciences Inc. and Shiseido Company, Limited announced collaboration and technology development transfer framework agreement for RepliCel’s RCH-01 hair regeneration technology.

Increasing prevalence of Alopecia Areata and higher focus on advancing research in North America are expected to bolster the market growth

North America holds a dominant position in the global alopecia treatment market, owing to the increasing prevalence of Alopecia Areata and active research activities by market players. For instance, according to the National Alopecia Areata Foundation (NAAF), 2017, alopecia areata affects around 6.8 million people in the U.S. with a lifetime risk of 2.1%.

Moreover, the NAAF is focused on broadening research efforts through two committees, including the Basic Research Advisory Council (BRAC), and the Clinical Research Advisory Council (CRAC), in order to advance the Alopecia Areata Treatment Development Program

Increasing acquisition strategies in the region by the market players are major factor expected to propel the market growth. For instance, in August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., which expanded Aclaris inflammation and immunology pipeline with the addition of Confluence lead product candidates CDD-450, topical Janus kinase inhibitors, and IL2-inducible T-cell kinase inhibitor programs.

Moreover, a collaboration of market players with regulatory authorities as well as other government organizations is further expected to support growth of the North America alopecia treatment market over the forecast period.

For instance, in April 2019, Precision Therapeutics Inc., Helomics, and the National Alopecia Areata Foundation (NAAF), entered into an agreement to treat people affected by an autoimmune skin disease called alopecia areata.

The agreement was intended to provide a next-generation patient registry to drive research on new treatments for people with this disease.

Key Players

Major players operating in the global alopecia treatment market include Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., Merck &amp; Co., Inc., Daiichi Sankyo Company, Limited, and Sun Pharmaceutical Industries Ltd.

Global Alopecia Treatment Market and Market Insights

Source

Previous Posts

Oral Presentation of CTP-543

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting

Concert Pharmaceuticals, Inc. today announced that results from its CTP-543 Phase 2 dose-ranging trial in alopecia areata have been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 20-24, 2020, in Denver, CO.

The details of the presentation, which will include new analyses from the Company’s completed Phase 2 dose-ranging study, are as follows:

  • Title: Oral JAK1/JAK2 Inhibitor CTP-543 Achieves Primary Endpoint in Patients with Alopecia Areata
  • Date and Time: Saturday, March 21, 2020, 9:00 AM – 12:00 PM
  • Session: S027 – Late-Breaking Research: Clinical Trials
  • Room: Bellco Theatre 2

About CTP-543 and Alopecia Areata

CTP-543 is an oral inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543 for alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body.

Alopecia areata may affect up to 650,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.

Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression.

There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI was to bring patient perspectives into an earlier stage of product development.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.

For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Source

Previous Posts

 

Alopecia Treatment Market

Androgenetic Alopecia Pipeline Insight 2020

Androgenetic Alopecia – Pipeline Insight 2020

Androgenetic Alopecia pipeline insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the androgenetic alopecia market. A detailed picture of the androgenetic alopecia pipeline landscape is provided, which includes the disease overview and androgenetic alopecia treatment guidelines.

The assessment part of the report embraces in-depth androgenetic alopecia commercial assessment and clinical assessment of the androgenetic alopecia pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, androgenetic alopecia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The Report Provides Insights into:

All of the companies that are developing therapies for the treatment of androgenetic alopecia with aggregate therapies developed by each company for the same.
Different therapeutic candidates segmented into early-stage, mid-stage and late stages of development for the androgenetic alopecia treatment.
Androgenetic alopecia key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of androgenetic alopecia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, sec filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Androgenetic Alopecia Analytical Perspective

In-Depth Androgenetic Alopecia Commercial Assessment of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Androgenetic alopecia clinical assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and moa type across this indication.

Scope of the report

The androgenetic alopecia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and moa type for androgenetic alopecia across the complete product development cycle, including all clinical and nonclinical stages.
It comprises of detailed profiles of androgenetic alopecia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
Detailed androgenetic alopecia research and development progress and trial details, results wherever available, are also included in the pipeline study.
Coverage of dormant and discontinued pipeline projects along with the reasons if available across androgenetic alopecia.

Report Highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for androgenetic alopecia.
in the coming years, the androgenetic alopecia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence androgenetic alopecia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
A detailed portfolio of major pharma players who are involved in fueling the androgenetic alopecia treatment market. Several potential therapies for androgenetic alopecia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the androgenetic alopecia market size in the coming years.
The in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of androgenetic alopecia ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

What are the current options for androgenetic alopecia treatment?
How many companies are developing therapies for the treatment of androgenetic alopecia?
What are the principal therapies developed by these companies in the industry?
How many therapies are developed by each company for the treatment of androgenetic alopecia?
How many androgenetic alopecia emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of androgenetic alopecia?
Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
What are the key collaborations (industry-industry, industry-academia), mergers and acquisitions, and major licensing activities that will impact androgenetic alopecia market?
Which are the dormant and discontinued products and the reasons for the same?
What is the unmet need for current therapies for the treatment of androgenetic alopecia?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing androgenetic alopecia therapies?
What are the clinical studies going on for androgenetic alopecia and their status?
What are the results of the clinical studies and their safety and efficacy?
What are the key designations that have been granted for the emerging therapies for androgenetic alopecia?
How many patents are granted and pending for the emerging therapies for the treatment of androgenetic alopecia?

Androgenetic Alopecia – Pipeline Insight 2020

Source

Previous Posts

Alopecia Treatment Market Insights

Alopecia Market 2027

Alopecia Market 2027

MARKET INTRODUCTION

Alopecia is a medical term, which is generally used for hair loss. It is a common autoimmune disorder that often results in unpredictable hair loss, which can lead to complete loss of hair on the scalp or, in uttermost cases, the entire body. This extreme condition can affect anyone irrespective of gender and age. Medications such as Minoxidil or Rogaine are the topical agents that are used for the treatment of disease. Other treatments of alopecia include medications that are sometimes used for other autoimmune disorders.

MARKET DYNAMICS

The alopecia market is anticipated to grow in the forecast, owing to the increasing prevalence of alopecia areata and Rise in incidence of chronic disorders such as, cancer, polycystic ovary syndrome (PCOS), hyperthyroidism, hypothyroidism, acute stress disorder, hypopituitarism, lupus. However, the rising awareness among people about hair loss is likely to add novel opportunities in the forecast period.

MARKET SCOPE

The “Global Alopecia Market Analysis to 2027” is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of alopecia market with detailed market segmentation by disease type, drug type, route of administration, distribution channel and geography. The global alopecia market is expected to witness high growth during the forecast period. The report provides key information on the market status of the leading alopecia market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global alopecia market is segmented on the basis of disease type, drug type, route of administration and distribution channel. Based on disease type, the market is classified as, alopecia areata, androgenic alopecia, alopecia totalis, ciatricial alopecia and traction alopecia. Based on the drug type, the market is segmented into minoxidil, finasteride and other drug types. On the basis of route of administration, the market is categorized as oral, topical and injectable. Based on the distribution channel, the market is segmented as hospitals, retail pharmacies and online pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global alopecia market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The alopecia market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting alopecia market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the alopecia market in these regions.

MARKET PLAYERS

The report covers key developments in the alopecia market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from alopecia market are anticipated to have lucrative growth opportunities in the future with the rising demand for alopecia market in the global market. Below mentioned is the list of few companies engaged in the alopecia market.

The report also includes the profiles of key alopecia market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

CAPILLUS
Sun Pharmaceutical Industries Ltd.
Cipla Inc.
Merck and Co., Inc.
Transitions Hair
Follica, Inc.
Johnson and Johnson Services, Inc.
Concert Pharmaceuticals
HCell Inc.

Alopecia Market 2027

Source

Previous Posts

Alopecia Treatment Market

Alopecia Market 2027 By Disease Type

Alopecia Market 2027 By Disease Type

MARKET INTRODUCTION

Alopecia is a medical term, which is generally used for hair loss. It is a common autoimmune disorder that often results in unpredictable hair loss, which can lead to complete loss of hair on the scalp or, in uttermost cases, the entire body.

This extreme condition can affect anyone irrespective of gender and age. Medications such as Minoxidil or Rogaine are the topical agents that are used for the treatment of disease. Other treatments of alopecia include medications that are sometimes used for other autoimmune disorders.

MARKET DYNAMICS

The alopecia market is anticipated to grow in the forecast, owing to the increasing prevalence of alopecia areata and Rise in incidence of chronic disorders such as cancer, polycystic ovary syndrome (PCOS), hyperthyroidism, hypothyroidism, acute stress disorder, hypopituitarism, lupus.

However, rising awareness among people about hair loss is likely to add novel opportunities in the forecast period.

MARKET SCOPE

The “Global Alopecia Market Analysis to 2027” is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis.

The report aims to provide an overview of alopecia market with detailed market segmentation by disease type, drug type, route of administration, distribution channel and geography. The global alopecia market is expected to witness high growth during the forecast period. The report provides key information on the market status of the leading alopecia market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global alopecia market is segmented on the basis of disease type, drug type, route of administration and distribution channel. Based on disease type, the market is classified as, alopecia areata, androgenic alopecia, alopecia totalis, ciatricial alopecia and traction alopecia.

Based on the drug type, the market is segmented into minoxidil, finasteride and other drug types. On the basis of route of administration, the market is categorized as oral, topical and injectable. Based on the distribution channel, the market is segmented as hospitals, retail pharmacies and online pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information.

It provides an overview and forecast of the global alopecia market based on various segments. It also provides market size and forecast estimates from the year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America.

The alopecia market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting alopecia market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the alopecia market in these regions.

MARKET PLAYERS

The report covers key developments in the alopecia market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations.

These activities have paved the way for the expansion of business and customer base of market players. The market players from alopecia market are anticipated to have lucrative growth opportunities in the future with the rising demand for alopecia market in the global market. Below mentioned is the list of few companies engaged in the alopecia market.

The report also includes the profiles of key alopecia market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of the last 3 years, key development in the past five years.

CAPILLUS
Sun Pharmaceutical Industries Ltd.
Cipla Inc.
Merck and Co., Inc.
Transitions Hair
Follica, Inc.
Johnson and Johnson Services, Inc.
Concert Pharmaceuticals
HCell Inc.
GlaxoSmithKline plc.

The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Alopecia Market 2027 By Disease Type

Source

Previous Posts